Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST).

被引：0
|
作者：
Li, Jian
Chi, Ping
Kang, Yoon-Koo
Cao, Hui
George, Suzanne
Zhang, Jun
Zhang, Jian
Hu, Kang
Zhang, Lijia
Xu, Yanhua
机构：
[1] Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Minist Educ, Lab Carcinogenesis & Translat Res,Dept Gastrointe, Beijing, Peoples R China
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[3] Univ Ulsan, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[4] Shanghai Jiao Tong Univ, Renji Hosp, Dept Gastrointestinal Surg, Sch Med, Shanghai, Peoples R China
[5] Dana Farber Canc Inst, Dept Med Oncol, Sarcoma Ctr, Boston, MA USA
[6] Chongqing Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Chongqing, Peoples R China
[7] Fudan Univ, Dept Med Oncol, Phase 1 Clin Trial Ctr, Shanghai Canc Hosp, Shanghai, Peoples R China
[8] Ningbo Newbay Technol Dev Co Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11518
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST)
    Blay, J.
    Casali, P. G.
    Reichardt, P.
    Kang, Y. K.
    Rutkowski, P.
    Gelderblom, H.
    Hohenberger, P.
    Kappeler, C.
    Kuss, I.
    Demetri, G. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S884 - S885
  • [22] Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST)
    Bauer, S.
    Blay, J-Y
    Casali, P. G.
    Reichardt, P.
    Kang, Y-K.
    Rutkowski, P.
    Gelderblom, H.
    Hohenberger, P.
    Kappeler, C.
    Kuss, I.
    Demetri, G. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 58 - 59
  • [23] Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
    Xuechao Liu
    Guangfeng Wang
    Xianglei Yan
    Haibo Qiu
    Ping Min
    Miaoyi Wu
    Chunyang Tang
    Fei Zhang
    Qiuqiong Tang
    Saijie Zhu
    Miaozhen Qiu
    Wei Zhuang
    Douglas D. Fang
    Zhiwei Zhou
    Dajun Yang
    Yifan Zhai
    Cell & Bioscience, 9
  • [24] Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
    Liu, Xuechao
    Wang, Guangfeng
    Yan, Xianglei
    Qiu, Haibo
    Min, Ping
    Wu, Miaoyi
    Tang, Chunyang
    Zhang, Fei
    Tang, Qiuqiong
    Zhu, Saijie
    Qiu, Miaozhen
    Zhuang, Wei
    Fang, Douglas D.
    Zhou, Zhiwei
    Yang, Dajun
    Zhai, Yifan
    CELL AND BIOSCIENCE, 2019, 9 (01):
  • [25] Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
    Janku, Filip
    Abdul Razak, Albiruni R.
    Chi, Ping
    Heinrich, Michael C.
    von Mehren, Margaret
    Jones, Robin L.
    Ganjoo, Kristen
    Trent, Jonathan
    Gelderblom, Hans
    Somaiah, Neeta
    Hu, Simin
    Rosen, Oliver
    Su, Ying
    Ruiz-Soto, Rodrigo
    Gordon, Michael
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (28) : 3294 - 3303
  • [26] Detection of KIT mutants in circulating tumor DNA (ctDNA) and their association with ponatinib anti-tumor activity in patients (pts) with advanced gastrointestinal stromal tumors (GIST)
    Heinrich, Michael C.
    Hodgson, J. Graeme
    von Mehren, Margaret
    Demetri, George D.
    Fletcher, Jonathan A.
    Sun, Jichao G.
    Pritchard, Justin R.
    Zhang, Sen
    Rivera, Victor M.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] Circulating tumor DNA (ctDNA) analyses of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor (GIST).
    Serrano, Cesar
    Bauer, Sebastian
    Gomez-Peregrina, David
    Kang, Yoon-Koo
    Jones, Robin L.
    Rutkowski, Piotr
    Mir, Olivier
    Heinrich, Michael C.
    Tap, William D.
    Newberry, Kate
    Grassian, Alexandra
    Miller, Stephen G.
    Shi, Hongliang
    Schoffski, Patrick
    Pantaleo, Maria A.
    Von Mehren, Margaret
    Trent, Jonathan C.
    George, Suzanne
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Zalcberg, J. R.
    Heinrich, M.
    George, S.
    Bauer, S.
    Gelderblom, H.
    Schoffski, P.
    Serrano, C.
    Jones, R. L.
    Attia, S.
    D'Amato, G.
    Chi, P.
    Reichardt, P.
    Meade, J. N.
    Reichert, V.
    Shi, K.
    Ruiz-Soto, R.
    von Mehren, M.
    Blay, J-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S973 - S974
  • [29] Clinical benefit with ripretinib as ≥4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Bauer, S.
    Heinrich, M.
    George, S.
    Zalcberg, J. R.
    Gelderblom, H.
    Schoffski, P.
    Serrano, C.
    Jones, R. L.
    Attia, S.
    D'Amato, G.
    Chi, P.
    Reichardt, P.
    Meade, J. N.
    Reichert, V
    Shi, K.
    Ruiz-Soto, R.
    von Mehren, M.
    Blay, J. -Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 11 - 11
  • [30] Clinicopathological significance of the c-KIT and PDGFRα gene mutations in patients with localized gastrointestinal stromal tumors:: A study of the Spanish Research Sarcoma Group (GEIS)
    Llombart-Bosch, A
    Lopez-Guerrero, JA
    Calabuig, S
    Martin, J
    Ramos, R
    Ortega, L
    Pellin, A
    LABORATORY INVESTIGATION, 2005, 85 : 111A - 111A
12345